Original study
A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm

https://doi.org/10.1016/0167-5273(94)90211-9Get rights and content

Abstract

Eighty-seven patients with recent onset atrial fibrillation (≤8 days) without clinical signs of heart failure were randomly allocated to one of the following treatments: (i) oral propafenone (600 mg as a loading dose followed after 8 h by 300 mg t.i.d.); (ii) intravenous digoxin as acute scheme (up to 1.125 mg/24 h) followed after 6 h by hydroquinidine chlorhydrate (total dose, 1350 mg); or (iii) placebo. The patients were submitted to Holter monitoring for 48 h. Results: propafenone achieved higher successful conversion rates at 6, 12 and 24 h compared either with placebo (62% vs. 17%, 83% vs. 34%; 86% vs. 55%; P < 0.01, respectively) or with digoxin at 6 h (62% vs. 38%; P < 0.05) and digoxin plus quinidine at 12 h (83% vs. 48%; P < 0.05). At 48 h, a placebo conversion rate of 76% was observed with consequent lack of any significant difference with the active treatments. Mean conversion times within 48 h were 267 ± 238 min for propafenone, 648 ± 631 min for digoxin plus quinidine (P < 0.01 vs. propafenone) and 893 ± 622 min for placebo (P < 0.001 vs. propafenone). Propafenone and digoxin plasma levels were within the therapeutic range. Asymptomatic phases of atrial flutter with ≥2:1 atrio-ventricular conduction ratio were observed during Holter monitoring, before conversion to sinus rhythm, in four patients treated with propafenone, in one patient taking digoxin plus quinidine and in four patients with placebo. One patient experienced syncope while standing up, 8 h after the beginning of propafenone treatment, due to a 1:1 atrial flutter with aberrant ventricular conduction. In conclusion, propafenone as an oral loading dose followed by oral treatment is highly and quickly effective in converting recent onset atrial fibrillation to sinus rhythm compared with placebo. Digoxin and digoxin plus quinidine, at the doses employed, had a lower success rate and more prolonged conversion times. The high rate of conversion to sinus rhythm during placebo underlines the need for controlled studies in this subset of patients.

References (29)

  • M Sokolow

    The present status of therapy of the cardiac arrhythmias with quinidine

    Am Heart J

    (1951)
  • B Margolis et al.

    Episodic drug treatment in the management of paroxysmal arrhythmias

    Am J Cardiol

    (1980)
  • WB Kannel et al.

    Epidemiologic features of chronic atrial fibrillation. The Framingham study

    N Engl J Med

    (1982)
  • RH Falk et al.

    Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized double-blinded trial

    Ann Intern Med

    (1987)
  • Cited by (114)

    View all citing articles on Scopus
    View full text